Your session is about to expire
← Back to Search
TG-1801 + Ublituximab for Lymphoma and Leukemia
Study Summary
This trial is testing a new drug, TG-1801, alone or in combination with another drug, ublituximab, in people with B-cell lymphoma or chronic lymphocytic leukemia.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- I have not had treatments targeting CD47/SIRPα or CD19.My CLL requires treatment according to iwCLL guidelines.I haven't had any cancer treatments or experimental drugs in the last 21 days.My non-Hodgkin lymphoma didn't respond to at least two treatments.My condition is B-cell non-Hodgkin lymphoma needing systemic treatment.I have at least one measurable lesion from chronic lymphocytic leukemia.I had a stem cell transplant using my own cells within the last 6 months.I have a lymphoma with a tumor larger than 1.5 cm.I have CLL/SLL or RT and my condition didn't improve after at least two treatments.My CLL has not improved after at least two treatments.
- Group 1: Cohort A: TG-1801
- Group 2: Cohort B: TG-1801
- Group 3: Cohort C: TG-1801 + Ublituximab
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Has there been previous experimentation with the drug TG-1801?
"Presently, 11 separate trials are exploring the efficacy of TG-1801 with 3 in Phase 3. These clinical studies span across 290 locations, particularly focusing on New york City."
Is this medical experiment pioneering in its field?
"At this time, 11 ongoing clinical trials are taking place in 133 cities and 13 countries related to the drug TG-1801. The first trial was run byTG Therapeutics, Inc. back in 2015 and included 600 participants who completed Phase 3 of the study with success; since then 9 other similar studies have been initiated."
Is TG-1801 cleared for public consumption by the Food and Drug Administration?
"The efficacy and safety of TG-1801 have yet to be established, so it was given a score of 1 on our scale. This is due to the fact that this drug is currently in phase 1 trials."
At what count of sites is this clinical trial currently being managed?
"This research initiative is currently enrolling participants from 5 separate sites. These include Chattanooga, Fayetteville and Nashville in addition to other nearby locations. To reduce the burden of traveling for prospective recruits, it is recommended that they select a clinic most proximal to their residence."
Are recruitment efforts still taking place for this research study?
"Affirmative. According to the clinicaltrials.gov listing, this medical study began recruiting on April 23rd 2021 and has recently been updated November 18th 2022. 60 patients are needed from 5 separate locations for this trial to be successful."
How extensive is the participant pool for this investigation?
"Affirmative, the information on clinicaltrials.gov displays that this experiment is actively seeking participants. This investigation was initially published on April 23rd 2021 and updated most recently on November 18th 2022. 60 individuals from five different sites need to be enlisted for it to launch successfully."
Share this study with friends
Copy Link
Messenger